ALIAXIN® EV

ALIAXIN® EV is a premium absorbable dermal filler designed specifically for professional aesthetic procedures. This advanced ALIAXIN formulation offers exceptional volumizing properties through its innovative blend of cross-linked hyaluronic acid (25 mg/g). 

ALIAXIN® EV Essential Volume delivers natural-looking results with long-lasting efficacy. Each package contains two pre-filled 1ml syringes and four sterile needles (27G), ensuring precise application for optimal treatment outcomes.

ALIAXIN® EV Dosage and Administration

For optimal results, ALIAXIN® EV should be administered by qualified medical professionals following these guidelines:

1. Disinfect the treatment area thoroughly
2. Use the provided 27G needles for precise injection
3. Inject evenly into the subcutaneous layer of the targeted area
4. Massage gently post-injection to distribute the product
5. Avoid excessive volume in any single area

The dermal filler should be injected into the subcutaneous tissue using appropriate techniques based on the specific facial region being treated. The outcome depends on skin type and the nature of the imperfection—the less evident the imperfection, the better the result.

Ingredient Information

ALIAXIN® EV represents the culmination of IBSA’s extensive research in hyaluronic acid technology. The formula contains:

• Cross-linked hyaluronic acid (25 mg/g)
• Phosphate buffered saline (1 g)

IBSA’s proprietary technology ensures different clinical results through specific combinations of hyaluronic acids with varying molecular weights, while precisely controlling the cross-linking grade. This unique approach delivers optimal viscoelastic properties tailored for volumizing treatments.

Storage Instructions

To maintain the integrity and efficacy of ALIAXIN® EV, please adhere to these storage guidelines:

• Store at 2–28°C

• Protect from freezing

• Keep away from direct sunlight

• Maintain in the original packaging until use

• Check the expiration date before administration

ALIAXIN® EV Contraindications

• Infective or inflammatory processes near the intervention area

• Ongoing cutaneous allergies

• Known hypersensitivity to components

• History of cheloid formation

• Immune system illnesses

• Serious pathological skin conditions

• Coagulation disorders or ongoing anticoagulant therapy

All patients should avoid substances affecting blood fluidity (aspirin, NSAIDs, Vitamin E) close to treatment to minimize potential bruising.

ALIAXIN® EV Precautions and Warnings

Medical professionals should take these precautions:

• Do not inject into areas with mammary, tendon, bone, or muscular implants

• Ensure proper patient selection based on medical history

• Perform a thorough consultation before treatment

• Do not mix with other products before injection

• Use only the provided needles for administration

• Dispose of all components according to medical waste protocols

Following treatment, patients should not expose the implanted areas to makeup, excessive heat (sun, UV tanning, laser), or intense cold until complete absorption of any swelling and redness.

ALIAXIN® EV Manufacturer and Regulatory Information

ALIAXIN® EV is manufactured by IBSA Farmaceutici Italia, a subsidiary of IBSA (Institut Biochimique SA), a globally recognized pharmaceutical company headquartered in Lugano, Switzerland. 

For authorized distribution, medical professionals should source these premium products only through recognized suppliers specializing in aesthetic solutions for licensed practitioners.